- Home
- PINE vs PROK Comparison
PINE vs PROK Comparison
Compare PINE & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PINE | PROK |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.5M | 269.7M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PINE | PROK |
|---|---|---|
| Price | $19.85 | $2.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $20.10 | $7.40 |
| AVG Volume (30 Days) | 113.4K | ★ 1.1M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 6.13% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $60,532,000.00 | $893,000.00 |
| Revenue This Year | $18.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 15.90 | ★ 1075.00 |
| 52 Week Low | $13.10 | $0.54 |
| 52 Week High | $20.80 | $7.13 |
Technical Indicators
Market Signals| Indicator | PINE | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 67.40 | 59.52 |
| Support Level | $13.88 | $2.09 |
| Resistance Level | $20.80 | $2.58 |
| Average True Range (ATR) | 0.38 | 0.14 |
| MACD | 0.17 | 0.04 |
| Stochastic Oscillator | 98.56 | 99.17 |
Price Performance
Historical ComparisonAbout PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.